Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA Puts Repros’ Proellex On Clinical Hold
FDA has placed Repros’ Proellex on clinical hold for safety reasons. This action follows the company’s voluntary decision to suspend dosing of all patients in clinical trials of
FDA has placed Repros’ Proellex on clinical hold for safety reasons. This action follows the company’s voluntary decision to suspend dosing of all patients in clinical trials of
Alnylam and Tekmira have reported that they will jointly participate in a new research collaboration focused on the discovery of novel cationic lipids and lipid nanoparticles, for the
Trubion Pharmaceuticals has posted revenue for the second quarter $4.1 million, compared to $4.5 million for the same period an year ago. For the six month ended period,
Watson has received a request for additional information from the Federal Trade Commission (FTC) in connection with Watson’s pending acquisition of Arrow Group. The information request was issued
Orexo’s partner, ProStrakan has submitted to FDA the New Drug Application (NDA) for Abstral, for the treatment of breakthrough cancer pain in opioid-tolerant patients. The company said that
The Dow Chemical Company, along with the American Chemistry Council and other chemical manufacturers, has released guidance for the modernization of US chemical safety laws in Washington DC.
Omnio Healer has entered into a partnership agreement with Eden Biodesign. Under the agreement, Eden Biodesign will provide process development and cGMP production services relating to Omnio Healer’s
Chesson Labs has received 510(k) market clearance from the FDA for NUVADERM, the company’s liquid bandage product. The FDA has cleared claims on the product to cover intact
Celgene has announced the presentation of final results from two company-sponsored studies of Amrubicin in relapsed small cell lung cancer (SCLC) at the 13th World Conference on Lung
Radius Health (Radius) has announced topline Phase 2 data demonstrating that in women with osteoporosis, BA058, the company’s novel PTHrP (parathyroid hormone-related protein) analog-significantly increased bone mineral density